Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: Correlation with clinicopathological parameters

Diseases of the Esophagus

Volumn 19, Issue 6, 2006, Pages 482-486

  Cheng, M F ^a   Tzao, C ^a   Tsai, W C ^a   Lee, W H ^a   Chen, A ^a   Chiang, H ^b   Sheu, L F ^a   Jin, J S ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b Taipei Institute of Pathology   (Taiwan)

Author keywords

CD147; EMMPRIN; Esophagus; Matriptase; Squamous cell carcinoma

Indexed keywords

CD147 ANTIGEN; MATRIPTASE;

ADULT; ADVANCED CANCER; AGED; ANTIGEN RETRIEVAL; ARTICLE; CANCER STAGING; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR CELL; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SERINE ENDOPEPTIDASES;

EID: 33750485799     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00613.x     Document Type: Article

References (30)

1. Pisani P, Parkin D M, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903.
2. Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics. CA Cancer J Clin 1999; 49: 8-31.
3. Ishibashi Y, Matsumoto T, Niwa M et al. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 2004; 101: 1994-2000.
4. Samantaray S, Sharma R, Chattopadhyaya T K, Gupta S D, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin 2004; 130: 37-44.
5. Yang G Z, Li L, Ding H Y, Zhou J S. Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: An immunohistochemical study. Exp Mol Pathol 2005; 79: 214-18.
6. Kelsen D P, Ginsberg R, Pajak T F et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-84.
7. Law S, Kwong D L, Kwok K F et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: Impact of chemoradiation and change in treatment strategy. Ann Surg 2003; 238: 339-47.
8. Sarbia M, Verreet P, Bittinger F et al. Basaloid squamous cell carcinoma of the esophagus: Diagnosis and prognosis. Cancer 1997; 79: 1871-8.
9. Kawakubo H, Ozawa S, Ando N et al. Alterations of p53, cyclin D1 and pRB expression in the carcinogenesis of esophageal squamous cell carcinoma. Oncol Rep 2005; 14: 1453-9.
10. Kuwano H, Kato H, Miyazaki T et al. Genetic alterations in esophageal cancer. Surg Today 2005; 35: 7-18.
11. Mandard A M, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 2000; 462: 335-42.
12. Hara T, Kijima H, Yamamoto S et al. Ubiquitous p63 expression in human esophageal squamous cell carcinoma. Int J Mol Med 2004; 14: 169-73.
13. Li Y, Stanley Z, Toole B P. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 2005; 93: 199-204.
14. Davidson B, Goldberg I, Berner A, Kristensen G B, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003; 20: 161-9.
15. Reimers N, Zafrakas K, Assmann V et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004; 10: 3422-8.
16. Lee S L, Dickson R B, Lin C Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-5.
17. Takeuchi T, Harris J L, Huang W, Yan K W, Coughlin S R, Craik C S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-42.
18. Oberst M, Anders J, Xie B et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001; 158: 1301-11.
19. Oberst M D, Johnson M D, Dickson R B et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002; 8: 1101-7.
20. Jin X, Hirosaki T, Lin C Y et al. Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin. J Cell Biochem 2005; 95: 632-47.
21. Miyauchi T, Kanekura T, Yamaoka A, Ozawa M, Miyazawa S, Muramatsu T. Basigin, a new, broadly distributed member of the immunoglobulin superfamily, has strong homology with both the immunoglobulin V domain and the beta-chain of major histocompatibility complex class II antigen. J Biochem 1990; 107: 316-23.
22. Guo H, Zucker S, Gordon M K, Toole B P, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 1997; 272: 24-7.
23. Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: Correlation with invasive growth of breast cancer. World J Surg 2000; 24: 334-40.
24. Rosenthal E L, Shreenivas S, Peters G E, Grizzle W E, Desmond R, Gladson C L. Expression of extracellular matrix metalloproteinase inducer in laryngeal squamous cell carcinoma. Laryngoscope 2003; 113: 1406-10.
25. Sameshima T, Nabeshima K, Toole B P et al. Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer 2000; 88: 21-7.
26. Lam S, Belldegrum A S, Figlin R A. Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin Cancer Res 2004; 10: 6304s-9s.
27. Gerdes J, Lemke H, Baisk H et al. Cell cycle analysis of the cell proliferation associated human nuclear antigen defined by the monoclonal antiboby Ki67. J Immunol 1984; 133: 1710-5.
28. Lin C Y, Wang J K, Torri J, Dou L, Sang Q A, Dickson R B. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. J Biol Chem 1997; 272: 9147-52.
29. Lee J W, Song S Y, Choi J J et al. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 2005; 36: 626-33.
30. Kang J Y, Dolled-Filhart M, Ocal I T et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63: 1101-5.